This collection of 3 articles explore the HBOT treatment and recovery of COVID-19 patients in Louisiana; with subsequent webinar discussion with the hospital’s doctors:
HBOT RECOVERY OF 6 COVID-19 MEDICAL STAFF IN ICU AT OPELOUSAS GENERAL HOSPITAL
(TRIAL COMPLETED) This clinical trial took place during w/c 13 April 2020, treating 6 COVID-19 positive hospital medical staff in ICU with deteriorating conditions and falling oxygen saturation despite a high-flow O2 supply. Patients also had multiple high-factors for complications with COVID-19 including Obesity, Diabetes, Hypertension, Sleep Apnea, Lupus, Hyperthyroidism, Hypoxia and Viral Pneumonia. Following the go-ahead from hospital administration for off-label compassionate use with consent, HBOT/COVID-19 treatment commenced at the hospital’s onsite hyperbaric facility. Patients received one 90-minute HBOT session at 2 atm pressure per day. Each HBOT session resulted in significant and incremental improvement. Breathing normalized, O2 saturation optimized, patients were more alert and less symptomatic. No barotrauma was experienced. After 3 or 4 days, all COVID-19 patients improved sufficiently to be moved out of ICU and off high-flow oxygen, and several were discharged from hospital within 10 days. (LARGE-SCALE HBOT TREATMENT NOW ON-GOING) Following the successful outcome of HBOT treatment of medical staff, each COVID-19 positive patient is now assessed for HBOT treatment. Selection criteria includes any COVID-19 patient with breathlessness and requiring high oxygen. So far, 11 COVID-19 patients are receiving and improving from HBOT treatment.
AAWC WEBINAR PRESENTED BY OPELOUSAS GENERAL HOSPITAL DOCTORS: THE ROLE OF HYPERBARIC OXYGEN IN THE TREATMENT OF COVID-19
SUMMARY: On 29 April 2020, the AAWC (Association for the Advancement of Wound Care) sponsored a highly informative 60-minute webinar on the use of HBOT for COVID-19 patients in ICU. Hosted by Dr Thomas Serena, past president of AAWC and Dr Kerry Thibodeaux and Dr Marcus Speyrer of Opelousas Medical Center in Louisiana, this webinar discussed the hospital’s successful HBOT/COVID-19 protocol. During this trial, and despite multiple high-risk conditions for COVID complications, all patients quickly improved – avoiding intubation and no longer requiring ICU. Several were discharged home within 1-2 weeks. HBOT treatments ranged from 1 to 9 sessions, one per day, with total number determined by patients recovery from breathlessness and their ability to be weaned to under 50% high-flow oxygen requirement. The hospital’s onsite hyperbaric facility makes transfer from ICU viable and safe. It was noted that Dr Thibodeaux and his team are well-versed in critical care patient management, and met with security, housekeeping, administration and legal departments prior to initiating their protocol to ensure immediate cleaning of the chamber, ICU room and pathway between both locations. The team separated their HBOT-prescribed non-COVID patients, treating them in the morning, and COVID ICU patients treated in the afternoon. Following the trial’s success, a wider HBOT/COVID-19 treatment protocol is now underway at the hospital.WATCH WEBINAR
HBOT FOR COVID-19 PRESENTATION– EXTRACT FROM AAWC WEBINAR
Here you will find a selection of key slides taken from the 60-minute AAWC webinar entitled The Role of Hyperbaric Oxygen in the Treatment of COVID-19, as presented by Dr Thomas Serena, past president of AAWC, and Dr Kerry Thibodeaux and Dr Marcus Speyrer of Opelousas Medical Center in Louisiana.VIEW PRESENTATION